SCHEMBL4499665

SCHEMBL4499665

CCC(C(N)=O)N1CCC(C(=O)OC)CC1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.51
CA2 P00918 4/20 0.51
CA4 P22748 4/20 0.51
CA6 P23280 4/20 0.51
CA7 P43166 4/20 0.51
CA9 Q16790 4/20 0.51
CA13 Q8N1Q1 4/20 0.51
CA12 O43570 3/20 0.51
CA14 Q9ULX7 3/20 0.51
CA5B Q9Y2D0 3/20 0.51
LMNA P02545 1/20 0.51
CA3 P07451 1/20 0.51
CA5A P35218 1/20 0.51
BRD4 O60885 1/20 0.47
GAA P10253 2/20 0.42
ALDH1A1 P00352 2/20 0.41
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.39
MAPT P10636 1/20 0.38
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL563946 0.89 BRD4 (0.53) CA1CA2CA4CA6CA7
SCHEMBL562860 0.89 BRD4 (0.53) CA1CA2CA4CA6CA7
SCHEMBL4499254 0.81 CA1 (0.51) CA1CA2CA4CA6CA7
SCHEMBL4497521 0.81 CA1 (0.51) CA1CA2CA4CA6CA7
SCHEMBL564115 0.81 BRD4 (0.50) CA1CA2CA4CA6CA7
SCHEMBL4493411 0.81 CA1 (0.51) CA1CA2CA4CA6CA7
SCHEMBL27494583 0.81 BRD4 (0.50) CA1CA2CA4CA6CA7
SCHEMBL4519294 0.78 LMNA (0.47) CA1CA2CA4CA6CA7
SCHEMBL2520005 0.77 LMNA (0.51) CA1CA2CA4CA6CA7
SCHEMBL660674 0.77 LMNA (0.52) CA1CA2CA4CA6CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473697-B2 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB S.A. (BE) 2009-01-06 US disclosed
US-20060258704-A1 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders MICHEL PHILIPPE 2006-11-16 US disclosed
US-7087596-B2 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB, S.A. (BE) 2006-08-08 US disclosed
US-20040132717-A1 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders UCB, S.A. (BE) 2004-07-08 US disclosed
EP-1395560-A1 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS UCB, S.A. (BE) 2004-03-10 EP disclosed
WO-2002094787-A1 2-OXO-PIPERIDINYL- AND 2-OXO-AZEPANYL ALKANOIC ACID DERIVATIV ES FOR THE TREATMENT OF EPILEPSY AND OTHER NEUROLOGICAL DISORDERS UCB, S.A. (BE) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132717-A1 2-Oxo-piperidinyl-and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders GABRA6, GABRA2, HCAR2 CA1 723/4885CA2 541/4885CA4 1971/4885
US-20060258704-A1 2-Oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivatives for the treatment of epilepsy and other neurological disorders GABRA6, HCAR2, GABRA2 CA1 764/4885CA2 539/4885CA4 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.